462 related articles for article (PubMed ID: 26188764)
1. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Watkins PB; Lewis JH; Kaplowitz N; Alpers DH; Blais JD; Smotzer DM; Krasa H; Ouyang J; Torres VE; Czerwiec FS; Zimmer CA
Drug Saf; 2015 Nov; 38(11):1103-13. PubMed ID: 26188764
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Lee J; Hoke ME; Estilo A; Sergeyeva O
Clin J Am Soc Nephrol; 2020 Dec; 16(1):48-58. PubMed ID: 33376102
[TBL] [Abstract][Full Text] [Related]
4. A
Shoaf SE; Ouyang J; Sergeyeva O; Estilo A; Li H; Leung D
Clin J Am Soc Nephrol; 2020 May; 15(5):643-650. PubMed ID: 32241780
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
6. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
[TBL] [Abstract][Full Text] [Related]
7. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Koch G; Ouyang J; McQuade RD; Blais JD; Czerwiec FS; Sergeyeva O;
N Engl J Med; 2017 Nov; 377(20):1930-1942. PubMed ID: 29105594
[TBL] [Abstract][Full Text] [Related]
8. Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression.
Raina R; Chakraborty R; DeCoy ME; Kline T
Pediatr Res; 2021 Mar; 89(4):894-899. PubMed ID: 32392574
[TBL] [Abstract][Full Text] [Related]
9. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.
Muto S; Kawano H; Higashihara E; Narita I; Ubara Y; Matsuzaki T; Ouyang J; Torres VE; Horie S
Clin Exp Nephrol; 2015 Oct; 19(5):867-77. PubMed ID: 25663351
[TBL] [Abstract][Full Text] [Related]
10. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
Blair HA; Keating GM
Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
[TBL] [Abstract][Full Text] [Related]
11. Review of tolvaptan for autosomal dominant polycystic kidney disease.
Baur BP; Meaney CJ
Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial.
Muto S; Okada T; Yasuda M; Tsubouchi H; Nakajima K; Horie S
Drug Healthc Patient Saf; 2017; 9():93-104. PubMed ID: 29123425
[TBL] [Abstract][Full Text] [Related]
13. Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
Mekahli D; Guay-Woodford LM; Cadnapaphornchai MA; Greenbaum LA; Litwin M; Seeman T; Dandurand A; Shi L; Sikes K; Shoaf SE; Schaefer F
Clin J Am Soc Nephrol; 2023 Jan; 18(1):36-46. PubMed ID: 36719158
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
16. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
17. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Casteleijn NF; Blais JD; Chapman AB; Czerwiec FS; Devuyst O; Higashihara E; Leliveld AM; Ouyang J; Perrone RD; Torres VE; Gansevoort RT;
Am J Kidney Dis; 2017 Feb; 69(2):210-219. PubMed ID: 27856088
[TBL] [Abstract][Full Text] [Related]
18. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
Muto S; Okada T; Shibasaki Y; Ibuki T; Horie S
Clin Exp Nephrol; 2021 Sep; 25(9):1003-1010. PubMed ID: 34089122
[TBL] [Abstract][Full Text] [Related]
19. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
[TBL] [Abstract][Full Text] [Related]
20. Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.
Woodhead JL; Brock WJ; Roth SE; Shoaf SE; Brouwer KL; Church R; Grammatopoulos TN; Stiles L; Siler SQ; Howell BA; Mosedale M; Watkins PB; Shoda LK
Toxicol Sci; 2017 Jan; 155(1):61-74. PubMed ID: 27655350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
